Numinus Wellness Inc. announced that its research site, Cedar Clinical Research (CCR), has been selected for Cybin's Phase 3 pivotal multinational clinical trial of CYB003. Aimed at revolutionizing the treatment of Major Depressive Disorder (MDD), this collaboration marks a pivotal moment in the journey toward understanding and treating one of the most debilitating mental health conditions affecting over 20 million Americans. The choice of CCR as a trial site underscores Numinus's commitment to advancing traditional and innovative behavioral health treatments.

It is a testament to the company's dedication to fostering safe, evidence-based novel therapies that have the potential to significantly impact patient care. CCR's Murray, Utah location will be one of the 15 U.S. sites chosen for this groundbreaking study. Cybin's Phase 2 trial results, where 75% of participants achieved remission from depression symptoms four months after dosing with CYB003, not only showcased the compound's promising impact, but also led to the U.S. Food and Drug Administration (FDA) granting it breakthrough therapy designation.

The Phase 3 trial, set to begin enrollment in mid-2024, will delve deeper into CYB003's safety and efficacy. Under the leadership of Dr. Paul Thielking, Numinus's Chief Science Officer and the trial's Principal Investigator, the study aims to further explore CYB003's potential to address a critical unmet need in mental health care.